BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer
R. Muthuswami, L. Bailey, R. Rakesh, A. Imbalzano, J. Nickerson, J. W. Hockensmith
This study shows BRG1 is elevated in prostate tumors and correlates with poor survival, and a BRG1 inhibitor reduces tumor growth and improves survival in xenograft models.
bioRxiv · Dec 27, 2018Cancer Biology